March 18, 2019 Clinical Research/Diagn. Life Science Tools PR/Corporate

NanoString Technologies Announces Commencement of Public Offering of Common Stock

SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an underwritten public offering of 4,500,000 shares of its common stock pursuant to its shelf registration statement. NanoString intends to offer and sell, subject to market and other conditions, 2,500,000 shares of common stock, and Clarus... Read more

December 19, 2018 Clinical Research/Diagn.

United Kingdom’s National Institute for Health and Care Excellence (NICE) Recommends NanoString’s Prosigna Breast Cancer Gene Signature Assay to Guide Chemotherapy Treatment Decisions for Qualified Early-Stage Invasive Breast Cancer Patients

PDF Version SEATTLE, Dec. 19, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that health officials from the National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued a recommendation that includes the use of the Prosigna® Breast Cancer Gene Signature Assay result to... Read more

November 8, 2018 Life Science Tools Product Launch

NanoString Announces Launch of CAR-T Characterization Panel for use in Development and Manufacturing

PDF Version SEATTLE, Nov. 08, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of a new gene expression panel for the molecular characterization of CAR-T cells in research, development and manufacturing. The nCounter® CAR-T Characterization Panel was created in collaboration with eight leading centers... Read more

October 29, 2018 Clinical Research/Diagn. M&A, Partnerships

MacroGenics and NanoString Enter Translational Research Collaboration to Identify and Develop Biomarkers in Immuno-Oncology

PDF Version Translational Research Initiative Will Use PanCancer IO 360 Panel to Identify Predictive Signatures for MGD013 SEATTLE, Oct. 29, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that MacroGenics(NASDAQ:MGNX) and NanoString have entered into a translational research agreement to identify and develop biomarkers for MacroGenics’ MGD013 program.... Read more

October 15, 2018 Clinical Research/Diagn. Life Science Tools PR/Corporate

NanoString Announces $100 Million Term Loan Facility with CRG

October 15, 2018 09:00 ET | Source: NanoString Technologies, Inc. SEATTLE, Oct. 15, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has entered into a new $100 million term loan facility with the CR Group L.P. (CRG), a health care focused... Read more

October 4, 2018 Life Science Tools PR/Corporate

NanoString Announces the University of Oxford Selected as the Winning Recipient in GeoMx Digital Spatial Profiler Grant Program

PDF Version DSP to be Applied to Transplant Research of Regulatory T Cell Therapy in Kidney Transplantation SEATTLE, Oct. 04, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the University of Oxfordhas been selected as the winning recipient of a grant for a GeoMx™... Read more